PRKCB and lung adenocarcinoma: Further analysis using the TIMER2.0 database confirmed that in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), PRKCB expression was positively correlated with the infiltration of the aforementioned immune cells, with the strongest correlation observed with CD8+ T cells (R = 0.325, P < 0.001) (Figures 5E, F; Supplementary Figures 2A–D).